Drug price hikes can damage company reputations: White House
- Wall St. drops on bleak GE outlook; Microsoft blunts losses
- British American Tobacco Offers to Acquire Remaining Shares of Reynolds American (RAI) for $56.50/Share
- General Electric (GE) Tops Q3 EPS by 2c; Updates FY16 EPS Outlook
- Pre-Open Stock Movers 10/21: (ALKS) (RAI) (PFPT) (MSFT) Higher; (SGY) (TWLO) (RRGB) Lower (more...)
- Oil on track for first weekly loss in five weeks on strong dollar
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
WASHINGTON (Reuters) - The White House on Wednesday said pharmaceutical firms risked damaging their reputations with big price hikes, but it sidestepped commenting directly on Mylan NV's decision to raise the price of its severe allergy treatment drug EpiPen.
"I'm obviously not going to make specific comments to specifically second guess the pricing strategy ... of one private enterprise," White House spokesman Josh Earnest said at a news briefing.
"I will observe, however, that pharmaceutical companies that often try to portray themselves as the inventors of life-saving medication often do real damage to their reputation by being greedy and jacking up prices," he said.
(Reporting by Timothy Ahmann, editing by G Crosse)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Theravance Biopharma and Mylan Announce Positive Results from Two Pivotal Phase 3 Studies of Revefenacin (TD-4208) for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)
- Polling safeguards stepped up after Trump's 'rigged election' claim
- Trump says he'll accept 'clear' election result, reserves right to challenge
Create E-mail Alert Related CategoriesGeneral News, Reuters
Related EntitiesRaising Prices
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!